Jasper Therapeutics (JSPR) Competitors $2.97 +0.12 (+4.21%) Closing price 04:00 PM EasternExtended Trading$2.84 -0.13 (-4.21%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. THTX, CLLS, BHST, CTOR, NKTX, KYTX, BDTX, FTLF, CGEN, and PLXShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Theratechnologies (THTX), Cellectis (CLLS), BioHarvest Sciences (BHST), Citius Oncology (CTOR), Nkarta (NKTX), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), FitLife Brands (FTLF), Compugen (CGEN), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors Theratechnologies Cellectis BioHarvest Sciences Citius Oncology Nkarta Kyverna Therapeutics Black Diamond Therapeutics FitLife Brands Compugen Protalix BioTherapeutics Jasper Therapeutics (NASDAQ:JSPR) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Do analysts rate JSPR or THTX? Jasper Therapeutics presently has a consensus price target of $29.75, indicating a potential upside of 901.68%. Given Jasper Therapeutics' higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in JSPR or THTX? 79.9% of Jasper Therapeutics shares are owned by institutional investors. 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor JSPR or THTX? In the previous week, Jasper Therapeutics had 6 more articles in the media than Theratechnologies. MarketBeat recorded 7 mentions for Jasper Therapeutics and 1 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 1.88 beat Jasper Therapeutics' score of 0.31 indicating that Theratechnologies is being referred to more favorably in the news media. Company Overall Sentiment Jasper Therapeutics Neutral Theratechnologies Very Positive Which has stronger earnings and valuation, JSPR or THTX? Theratechnologies has higher revenue and earnings than Jasper Therapeutics. Theratechnologies is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$71.27M-$5.24-0.57Theratechnologies$84.38M1.76-$8.31M-$0.19-17.00 Which has more volatility and risk, JSPR or THTX? Jasper Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Is JSPR or THTX more profitable? Jasper Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Theratechnologies' return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -109.45% -89.82% Theratechnologies -10.85%N/A -9.83% SummaryJasper Therapeutics and Theratechnologies tied by winning 8 of the 16 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.61M$3.08B$5.63B$9.81BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-0.5720.6830.1125.79Price / SalesN/A329.08430.20159.26Price / CashN/A40.7837.7258.50Price / Book0.727.718.476.07Net Income-$71.27M-$54.65M$3.26B$265.11M7 Day Performance2.41%3.95%3.56%2.90%1 Month Performance-15.38%11.46%5.97%3.99%1 Year Performance-84.24%13.04%42.70%26.92% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.9394 of 5 stars$2.97+4.2%$29.75+901.7%-83.0%$44.61MN/A-0.5720Earnings ReportTHTXTheratechnologiesN/A$3.20+0.3%N/A+139.6%$146.91M$85.87M0.00140CLLSCellectis2.7962 of 5 stars$2.65+1.9%$4.00+50.9%+30.4%$144.52M$49.22M0.00290Gap UpBHSTBioHarvest SciencesN/A$8.82+0.7%$13.67+55.0%N/A$143.88M$25.19M0.00N/ANews CoverageEarnings ReportHigh Trading VolumeCTORCitius Oncology1.5969 of 5 stars$1.72-5.0%$3.00+74.4%N/A$141.85MN/A0.00N/ANews CoverageNKTXNkarta2.0731 of 5 stars$2.01+1.5%$14.33+613.1%-61.3%$140.50MN/A0.00140News CoverageEarnings ReportAnalyst ForecastGap UpKYTXKyverna Therapeutics3.2721 of 5 stars$3.10-4.3%$15.60+403.2%-53.8%$140.03M$7.03M0.0096News CoverageBDTXBlack Diamond Therapeutics3.2301 of 5 stars$2.31-3.8%$12.40+436.8%-45.7%$136.65MN/A10.4490News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpFTLFFitLife Brands4.0325 of 5 stars$15.63+7.6%$20.50+31.2%+12.1%$136.36M$64.47M0.0020CGENCompugen1.9363 of 5 stars$1.50flat$4.00+166.7%-12.0%$133.86M$27.86M0.0070Earnings ReportAnalyst RevisionPLXProtalix BioTherapeutics3.6253 of 5 stars$1.61+4.5%$15.00+831.7%+56.2%$128.17M$59.76M-12.38200News CoverageInsider Trade Related Companies and Tools Related Companies Theratechnologies Alternatives Cellectis Alternatives BioHarvest Sciences Alternatives Citius Oncology Alternatives Nkarta Alternatives Kyverna Therapeutics Alternatives Black Diamond Therapeutics Alternatives FitLife Brands Alternatives Compugen Alternatives Protalix BioTherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access